Yes or No Is Not a Diagnosis
Five different companies walk into aninvestment committee. A binary vote can carry exactly one of them. The otherfour get rounded off — to yes, or to no — and the rounding error is where themoney goes to die.
The five are structurally different: readytoday; ready once two named conditions clear; carrying fixable breaks thatcapital would scale along with everything else; blocked from outside; unable toclear its blockers as constituted. Each implies a different capital action —which is the case for verdicts instead of votes: Go·Deploy, Go·Milestone,Revisit·Execution, Revisit·External, Pass.
And a verdict needs an address. Every tension aread surfaces sits somewhere: in the design (the plan wasn't buildable asdrawn), in current performance (the machine is underdelivering today), or underload (the break waiting at exactly the volume the capital is buying). Theunder-load column is the one traditional diligence cannot see — and it isreadable today. The failure hasn't happened yet; the evidence has.
The anatomy runs deeper: why a bridge without adiagnosis is an improvised verdict — capital deployed against a break nobodyhas named, a pier called a bridge. Why tension pairs read a company better thanany single metric — install rate against onboarding capacity, engineeringvelocity against field quality — one signal against another, so thecontradiction surfaces instead of averaging away. And why the crossing intocommoditized hardware has a clock on it: the window in which the pivot towardsoftware, services, and the ODM model is still fundable, before the captureprice and the cost curve close it.
What this means for your seat
If you hold family capital: The next time a committee reduces acomplex company to a yes/no vote, ask which of the five situations you'reactually in. Two of them deserve capital, two deserve capital only after namedconditions clear, and one deserves an honest no — and the binary can't tell youwhich.
If you run a fund: The under-load column is your edge if youclaim it: the break that arrives at exactly the volume your check is buying isreadable today, before the check. That reading is the difference betweenpricing risk and inheriting it.
If you lead a company: A Revisit verdict is not arejection — it's a map of what must clear before capital is safe in yourcompany, which is more than most term sheets will ever tell you. The companiesthat treat the diagnosis as an asset raise on better terms the second time.
The full essay on Under Load goes further: allfive verdicts with their capital actions, the serial-bridge arithmetic, the twolocalization questions, the Commoditization Cliff in full, and the withdrawalchain — what leaves Europe when the diagnosis never happens.